The diabetes drug space like any drug category is ultra-competitive and drug makers will look for any edge no matter how slight to gain an advantage. This is particularly true in a category that has commoditized. It’s a rare situation that any drug owns a category with little or no competition such as Lantus did years ago. Today no matter where you look in diabetes there are three sometimes more choices and like the device side most of these drugs do the same thing the same way.
As with every rule there is an exception as sometimes one . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.